OnCo
biomarkersBiomarker

FcRH5 expression

aka FcRH5, FCRL5 expression, FcRH5-positive

FcRH5 is a third myeloma surface target after BCMA and GPRC5D. Cevostamab, the FcRH5 x CD3 bispecific, is in phase 3; no approval or threshold exists yet.